WO2001031007A3 - Nucleic acid molecules derived from rat brain and programmed cell death models - Google Patents
Nucleic acid molecules derived from rat brain and programmed cell death models Download PDFInfo
- Publication number
- WO2001031007A3 WO2001031007A3 PCT/US2000/029132 US0029132W WO0131007A3 WO 2001031007 A3 WO2001031007 A3 WO 2001031007A3 US 0029132 W US0029132 W US 0029132W WO 0131007 A3 WO0131007 A3 WO 0131007A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- nucleic acid
- acid molecules
- cell death
- programmed cell
- useful
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4747—Apoptosis related proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Genetics & Genomics (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Abstract
The invention is directed to human homologs of nucleic acid molecules derived from rat brain and programmed cell death expression libraries. These molecules can constitute microarrays of expressed sequences useful for analyzing gene expression in various biological contexts, including development, differentiation, and disease, both in vivo and in vitro. The nucleic acid molecules are useful for diagnosis, treatment, and drug discovery. The nucleic acid molecules are useful for creating microarrays for transcriptional profiling. The invention further provides peptides encoded by the nucleic acid molecules, useful for methods of diagnosis, treatment, and drug discovery. The invention specifically relates to nucleic acid molecules involved in programmed cell death.
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP00972316A EP1226243A2 (en) | 1999-10-22 | 2000-10-20 | Nucleic acid molecules derived from rat brain and programmed cell death models |
| JP2001533988A JP2003512840A (en) | 1999-10-22 | 2000-10-20 | Rat brain-derived nucleic acid molecules and programmed cell death models |
| CA002388617A CA2388617A1 (en) | 1999-10-22 | 2000-10-20 | Nucleic acid molecules derived from rat brain and programmed cell death models |
| AU10996/01A AU1099601A (en) | 1999-10-22 | 2000-10-20 | Nucleic acid molecules derived from rat brain and programmed cell death models |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16118899P | 1999-10-22 | 1999-10-22 | |
| US60/161,188 | 1999-10-22 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| WO2001031007A2 WO2001031007A2 (en) | 2001-05-03 |
| WO2001031007A3 true WO2001031007A3 (en) | 2001-11-29 |
| WO2001031007A9 WO2001031007A9 (en) | 2002-05-10 |
Family
ID=22580209
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2000/029132 WO2001031007A2 (en) | 1999-10-22 | 2000-10-20 | Nucleic acid molecules derived from rat brain and programmed cell death models |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1226243A2 (en) |
| JP (1) | JP2003512840A (en) |
| AU (1) | AU1099601A (en) |
| CA (1) | CA2388617A1 (en) |
| WO (1) | WO2001031007A2 (en) |
Families Citing this family (105)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020081679A1 (en) * | 1999-10-22 | 2002-06-27 | Millennium Pharmaceuticals, Inc. | NARC8 programmed cell-death-associated molecules and uses thereof |
| EP1257572A2 (en) * | 2000-02-07 | 2002-11-20 | Millennium Pharmaceuticals, Inc. | Narc-1, subtilase-like homologs |
| US20030165863A1 (en) * | 2001-01-16 | 2003-09-04 | Millennium Pharmaceuticals, Inc. | NARC10 and NARC16, programmed cell death-associated molecules and uses thereof |
| US7572618B2 (en) | 2006-06-30 | 2009-08-11 | Bristol-Myers Squibb Company | Polynucleotides encoding novel PCSK9 variants |
| CA2669424A1 (en) | 2006-11-07 | 2008-05-29 | Merck & Co., Inc. | Antagonists of pcsk9 |
| WO2008109871A2 (en) * | 2007-03-08 | 2008-09-12 | Irm Llc | Crystal structure of proprotein convertase 9 (pcsk9) and uses thereof |
| US8263353B2 (en) | 2007-03-27 | 2012-09-11 | Merck Sharp & Dohme Corp. | Method for detecting autoprocessed, secreted PCSK9 |
| JOP20080381B1 (en) | 2007-08-23 | 2023-03-28 | Amgen Inc | Antigen Binding Proteins to Proprotein Convertase subtillisin Kexin type 9 (pcsk9) |
| AR070315A1 (en) | 2008-02-07 | 2010-03-31 | Merck & Co Inc | ANTIBODIES 1B20 ANTAGONISTS OF PCSK9 |
| AR070316A1 (en) | 2008-02-07 | 2010-03-31 | Merck & Co Inc | PCSK9 ANTAGONISTS (SUBTILISINE-KEXINA TYPE 9 PROPROTEIN) |
| US8748115B2 (en) | 2008-12-12 | 2014-06-10 | Merck Sharp & Dohme Corp. | PCSK9 immunoassay |
| US8802827B2 (en) | 2009-10-30 | 2014-08-12 | Merck Sharp & Dohme Corp. | AX1 PCSK9 antagonists |
| CA2777542A1 (en) | 2009-10-30 | 2011-05-05 | Merck Sharp & Dohme Corp. | Ax213 and ax132 pcsk9 antagonists and variants |
| AR087715A1 (en) | 2011-09-16 | 2014-04-09 | Lilly Co Eli | ANTI PCSK9 ANTIBODIES AND USES OF THE SAME |
| SI3081249T1 (en) | 2012-11-21 | 2021-03-31 | Amgen Inc. | Drug delivery device |
| CA2904725C (en) | 2013-03-15 | 2022-04-12 | Amgen Inc. | Drug cassette, autoinjector, and autoinjector system |
| EP3593839A1 (en) | 2013-03-15 | 2020-01-15 | Amgen Inc. | Drug cassette |
| CN113559363B (en) | 2013-03-22 | 2023-10-31 | 美国安进公司 | Syringe and method of assembly |
| MX2016005315A (en) | 2013-10-24 | 2016-08-11 | Amgen Inc | Drug delivery system with temperature-sensitive control. |
| KR102458637B1 (en) | 2013-10-24 | 2022-10-24 | 암겐 인코포레이티드 | Injector and method of assembly |
| US9023359B1 (en) | 2014-07-15 | 2015-05-05 | Kymab Limited | Targeting rare human PCSK9 variants for cholesterol treatment |
| US8980273B1 (en) | 2014-07-15 | 2015-03-17 | Kymab Limited | Method of treating atopic dermatitis or asthma using antibody to IL4RA |
| US9914769B2 (en) | 2014-07-15 | 2018-03-13 | Kymab Limited | Precision medicine for cholesterol treatment |
| US8986694B1 (en) | 2014-07-15 | 2015-03-24 | Kymab Limited | Targeting human nav1.7 variants for treatment of pain |
| US9034332B1 (en) | 2014-07-15 | 2015-05-19 | Kymab Limited | Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment |
| US9045548B1 (en) | 2014-07-15 | 2015-06-02 | Kymab Limited | Precision Medicine by targeting rare human PCSK9 variants for cholesterol treatment |
| US9017678B1 (en) | 2014-07-15 | 2015-04-28 | Kymab Limited | Method of treating rheumatoid arthritis using antibody to IL6R |
| US9045545B1 (en) | 2014-07-15 | 2015-06-02 | Kymab Limited | Precision medicine by targeting PD-L1 variants for treatment of cancer |
| US8992927B1 (en) | 2014-07-15 | 2015-03-31 | Kymab Limited | Targeting human NAV1.7 variants for treatment of pain |
| US9051378B1 (en) | 2014-07-15 | 2015-06-09 | Kymab Limited | Targeting rare human PCSK9 variants for cholesterol treatment |
| US8986691B1 (en) | 2014-07-15 | 2015-03-24 | Kymab Limited | Method of treating atopic dermatitis or asthma using antibody to IL4RA |
| US9067998B1 (en) | 2014-07-15 | 2015-06-30 | Kymab Limited | Targeting PD-1 variants for treatment of cancer |
| US8945560B1 (en) | 2014-07-15 | 2015-02-03 | Kymab Limited | Method of treating rheumatoid arthritis using antibody to IL6R |
| US8883157B1 (en) | 2013-12-17 | 2014-11-11 | Kymab Limited | Targeting rare human PCSK9 variants for cholesterol treatment |
| US10994112B2 (en) | 2014-02-05 | 2021-05-04 | Amgen Inc. | Drug delivery system with electromagnetic field generator |
| GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
| MX2016014561A (en) | 2014-05-07 | 2017-06-21 | Amgen Inc | Autoinjector with shock reducing elements. |
| EP4036924A1 (en) | 2014-06-03 | 2022-08-03 | Amgen, Inc | Devices and methods for assisting a user of a drug delivery device |
| US9150660B1 (en) | 2014-07-15 | 2015-10-06 | Kymab Limited | Precision Medicine by targeting human NAV1.8 variants for treatment of pain |
| US9139648B1 (en) | 2014-07-15 | 2015-09-22 | Kymab Limited | Precision medicine by targeting human NAV1.9 variants for treatment of pain |
| EP3943135A3 (en) | 2014-10-14 | 2022-06-29 | Amgen Inc. | Drug injection device with visual and audible indicators |
| EP3233163B1 (en) | 2014-12-19 | 2021-10-13 | Amgen Inc. | Drug delivery device with proximity sensor |
| JP2017538512A (en) | 2014-12-19 | 2017-12-28 | アムジエン・インコーポレーテツド | Drug delivery device including live button or user interface field |
| AU2016220141B2 (en) | 2015-02-17 | 2018-07-12 | Amgen Inc. | Drug delivery device with vacuum assisted securement and/or feedback |
| EP3261690B1 (en) | 2015-02-27 | 2021-12-15 | Amgen Inc. | Drug delivery device having a needle guard mechanism with a tunable threshold of resistance to needle guard movement |
| WO2017039786A1 (en) | 2015-09-02 | 2017-03-09 | Amgen Inc. | Syringe assembly adapter for a syringe |
| EP3386573B1 (en) | 2015-12-09 | 2019-10-02 | Amgen Inc. | Auto-injector with signaling cap |
| WO2017120178A1 (en) | 2016-01-06 | 2017-07-13 | Amgen Inc. | Auto-injector with signaling electronics |
| US11200298B2 (en) | 2016-03-15 | 2021-12-14 | Amgen Inc. | Reducing probability of glass breakage in drug delivery devices |
| US11541168B2 (en) | 2016-04-29 | 2023-01-03 | Amgen Inc. | Drug delivery device with messaging label |
| US11389588B2 (en) | 2016-05-02 | 2022-07-19 | Amgen Inc. | Syringe adapter and guide for filling an on-body injector |
| WO2017197222A1 (en) | 2016-05-13 | 2017-11-16 | Amgen Inc. | Vial sleeve assembly |
| EP3458988B1 (en) | 2016-05-16 | 2023-10-18 | Amgen Inc. | Data encryption in medical devices with limited computational capability |
| US11541176B2 (en) | 2016-06-03 | 2023-01-03 | Amgen Inc. | Impact testing apparatuses and methods for drug delivery devices |
| EP3478342A1 (en) | 2016-07-01 | 2019-05-08 | Amgen Inc. | Drug delivery device having minimized risk of component fracture upon impact events |
| US20190328965A1 (en) | 2016-08-17 | 2019-10-31 | Amgen Inc. | Drug delivery device with placement detection |
| EP3532127A1 (en) | 2016-10-25 | 2019-09-04 | Amgen Inc. | On-body injector |
| WO2018083248A1 (en) | 2016-11-03 | 2018-05-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
| KR20230125856A (en) | 2016-12-23 | 2023-08-29 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | Gene editing of pcsk9 |
| WO2018136398A1 (en) | 2017-01-17 | 2018-07-26 | Amgen Inc. | Injection devices and related methods of use and assembly |
| EP3582829A1 (en) | 2017-02-17 | 2019-12-25 | Amgen Inc. | Insertion mechanism for drug delivery device |
| MX2019009625A (en) | 2017-02-17 | 2019-10-09 | Amgen Inc | Drug delivery device with sterile fluid flowpath and related method of assembly. |
| WO2018165143A1 (en) | 2017-03-06 | 2018-09-13 | Amgen Inc. | Drug delivery device with activation prevention feature |
| MX2019010543A (en) | 2017-03-07 | 2019-10-21 | Amgen Inc | Needle insertion by overpressure. |
| IL268386B2 (en) | 2017-03-09 | 2023-11-01 | Amgen Inc | Insertion mechanism for drug delivery device |
| BR112019020053B1 (en) | 2017-03-28 | 2023-10-10 | Amgen Inc | MACHINE FOR ATTACHING A PLUS ROD TO A SYRINGE ASSEMBLY AND METHOD OF USING SAID MACHINE |
| AU2018282077B2 (en) | 2017-06-08 | 2023-11-23 | Amgen Inc. | Torque driven drug delivery device |
| AU2018280054B2 (en) | 2017-06-08 | 2023-07-13 | Amgen Inc. | Syringe assembly for a drug delivery device and method of assembly |
| EP3641857A1 (en) | 2017-06-22 | 2020-04-29 | Amgen Inc. | Device activation impact/shock reduction |
| WO2018237225A1 (en) | 2017-06-23 | 2018-12-27 | Amgen Inc. | Electronic drug delivery device comprising a cap activated by a switch assembly |
| EP3651832B1 (en) | 2017-07-14 | 2023-12-13 | Amgen Inc. | Needle insertion-retraction system having dual torsion spring system |
| WO2019018169A1 (en) | 2017-07-21 | 2019-01-24 | Amgen Inc. | Gas permeable sealing member for drug container and methods of assembly |
| JP7242562B2 (en) | 2017-07-25 | 2023-03-20 | アムジエン・インコーポレーテツド | Drug delivery device with container access system and associated method of assembly |
| MA49677A (en) | 2017-07-25 | 2021-04-21 | Amgen Inc | DRUG DELIVERY DEVICE WITH GEAR MODULE AND ASSOCIATED ASSEMBLY PROCESS |
| US20200164155A1 (en) | 2017-08-09 | 2020-05-28 | Amgen Inc. | Hydraulic-pneumatic pressurized chamber drug delivery system |
| WO2019036181A1 (en) | 2017-08-18 | 2019-02-21 | Amgen Inc. | Wearable injector with sterile adhesive patch |
| US11103636B2 (en) | 2017-08-22 | 2021-08-31 | Amgen Inc. | Needle insertion mechanism for drug delivery device |
| ES2939292T3 (en) | 2017-10-04 | 2023-04-20 | Amgen Inc | Flow adapter for drug delivery device |
| WO2019070552A1 (en) | 2017-10-06 | 2019-04-11 | Amgen Inc. | Drug delivery device with interlock assembly and related method of assembly |
| US11464903B2 (en) | 2017-10-09 | 2022-10-11 | Amgen Inc. | Drug delivery device with drive assembly and related method of assembly |
| EP3703779A1 (en) | 2017-11-03 | 2020-09-09 | Amgen Inc. | Systems and approaches for sterilizing a drug delivery device |
| EP3706830A1 (en) | 2017-11-06 | 2020-09-16 | Amgen Inc. | Drug delivery device with placement and flow sensing |
| WO2019090303A1 (en) | 2017-11-06 | 2019-05-09 | Amgen Inc. | Fill-finish assemblies and related methods |
| SG11202002966QA (en) | 2017-11-10 | 2020-05-28 | Amgen Inc | Plungers for drug delivery devices |
| MX2020005066A (en) | 2017-11-16 | 2020-08-20 | Amgen Inc | Autoinjector with stall and end point detection. |
| AU2018368340B2 (en) | 2017-11-16 | 2024-03-07 | Amgen Inc. | Door latch mechanism for drug delivery device |
| US10835685B2 (en) | 2018-05-30 | 2020-11-17 | Amgen Inc. | Thermal spring release mechanism for a drug delivery device |
| US11083840B2 (en) | 2018-06-01 | 2021-08-10 | Amgen Inc. | Modular fluid path assemblies for drug delivery devices |
| US20210260279A1 (en) | 2018-07-24 | 2021-08-26 | Amgen Inc. | Hybrid drug delivery devices with optional grip portion and related method of preparation |
| WO2020023336A1 (en) | 2018-07-24 | 2020-01-30 | Amgen Inc. | Hybrid drug delivery devices with grip portion |
| WO2020023444A1 (en) | 2018-07-24 | 2020-01-30 | Amgen Inc. | Delivery devices for administering drugs |
| MX2021000749A (en) | 2018-07-24 | 2021-03-29 | Amgen Inc | Delivery devices for administering drugs. |
| US20210228797A1 (en) | 2018-07-31 | 2021-07-29 | Amgen Inc. | Fluid path assembly for a drug delivery device |
| WO2020068623A1 (en) | 2018-09-24 | 2020-04-02 | Amgen Inc. | Interventional dosing systems and methods |
| EP3856283A1 (en) | 2018-09-28 | 2021-08-04 | Amgen Inc. | Muscle wire escapement activation assembly for a drug delivery device |
| CA3110529A1 (en) | 2018-10-02 | 2020-04-09 | Amgen Inc. | Injection systems for drug delivery with internal force transmission |
| EP3860686A1 (en) | 2018-10-05 | 2021-08-11 | Amgen Inc. | Drug delivery device having dose indicator |
| JP2022504769A (en) | 2018-10-15 | 2022-01-13 | アムジエン・インコーポレーテツド | Drug delivery device with damping mechanism |
| WO2020081480A1 (en) | 2018-10-15 | 2020-04-23 | Amgen Inc. | Platform assembly process for drug delivery device |
| MA54048A (en) | 2018-11-01 | 2022-02-09 | Amgen Inc | DRUG DELIVERY DEVICES WITH PARTIAL RETRACTION OF DRUG DELIVERY BODY |
| US20220031939A1 (en) | 2018-11-01 | 2022-02-03 | Amgen Inc. | Drug delivery devices with partial drug delivery member retraction |
| TWI831847B (en) | 2018-11-01 | 2024-02-11 | 美商安進公司 | Drug delivery devices with partial needle retraction and methods for operating the same |
| MX2021012557A (en) | 2019-04-24 | 2021-11-12 | Amgen Inc | Syringe sterilization verification assemblies and methods. |
| AU2020337250A1 (en) | 2019-08-23 | 2022-03-03 | Amgen Inc. | Drug delivery device with configurable needle shield engagement components and related methods |
| BR112023024278A2 (en) | 2021-05-21 | 2024-01-30 | Amgen Inc | METHOD OF OPTIMIZING A FILLING RECIPE FOR A DRUG CONTAINER |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998049297A1 (en) * | 1997-04-25 | 1998-11-05 | American Home Products Corporation | Neuronal mort1 isoforms |
-
2000
- 2000-10-20 AU AU10996/01A patent/AU1099601A/en not_active Abandoned
- 2000-10-20 CA CA002388617A patent/CA2388617A1/en not_active Abandoned
- 2000-10-20 EP EP00972316A patent/EP1226243A2/en not_active Withdrawn
- 2000-10-20 WO PCT/US2000/029132 patent/WO2001031007A2/en active Application Filing
- 2000-10-20 JP JP2001533988A patent/JP2003512840A/en not_active Withdrawn
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998049297A1 (en) * | 1997-04-25 | 1998-11-05 | American Home Products Corporation | Neuronal mort1 isoforms |
Non-Patent Citations (5)
| Title |
|---|
| AOKI TOMOKAZU ET AL: "Rat TAFII-31 gene is induced upon programmed cell death in differentiated PC12 cells deprived of NGF.", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 234, no. 1, 1997, pages 230 - 234, XP002163760, ISSN: 0006-291X * |
| DATABASE EMBL [online] 17 August 1999 (1999-08-17), BLAKEY S.: "KIAA1434", XP002163761, retrieved from EBI Database accession no. AL109935 * |
| DATABASE EMBL [online] 19 March 1999 (1999-03-19), POUSTKA A. ET AL.: "EST DKFZp434B2072_r1", XP002163762, retrieved from EBI Database accession no. AL046038 * |
| HEMACHANDRA REDDY P ET AL: "Transgenic mice expressing mutated full-length HD cDNA: A paradigm for locomotor changes and selective neuronal loss in Huntington's disease.", PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY OF LONDON B BIOLOGICAL, vol. 354, no. 1386, June 1999 (1999-06-01), June, 1999, pages 1035 - 1045, XP000990516, ISSN: 0962-8436 * |
| RICKMAN DENNIS W ET AL: "Characterization of the cell death promoter, Bad, in the developing rat retina and forebrain.", DEVELOPMENTAL BRAIN RESEARCH, vol. 115, no. 1, 8 June 1999 (1999-06-08), pages 41 - 47, XP000990537, ISSN: 0165-3806 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2388617A1 (en) | 2001-05-03 |
| WO2001031007A2 (en) | 2001-05-03 |
| AU1099601A (en) | 2001-05-08 |
| JP2003512840A (en) | 2003-04-08 |
| WO2001031007A9 (en) | 2002-05-10 |
| EP1226243A2 (en) | 2002-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2001031007A3 (en) | Nucleic acid molecules derived from rat brain and programmed cell death models | |
| WO2005063976A3 (en) | Methods for inducing differentiation of undifferentiated mammalian cells into osteoblasts | |
| WO2001066595A3 (en) | Human fgf-23 gene and gene expression products | |
| WO1998007850A3 (en) | Agents for pre-symptomatic detection and therapeutic targeting of alzheimer's disease and down syndrome in humans | |
| WO2007016532A3 (en) | Mutations and polymorphisms of hdac4 | |
| WO2004013310A3 (en) | Methods of down regulating target gene expression in vivo by introduction of interfering rna | |
| WO2002074992A3 (en) | Phosphodiesterase 4d genes related to human stroke | |
| AU2002330215A1 (en) | Nucleic acid molecules, polypeptides and uses therefor, including diagnosis and treatment of alzheimer's disease | |
| WO2004038381A3 (en) | Methods for drug discovery, disease treatment, and diagnosis using metabolomics | |
| WO2005121374A3 (en) | Molecular analysis of hair follicles for disease | |
| WO2007124820A3 (en) | Method for in vitro monitoring of postoperative changes following liver transplantation | |
| WO2002012440A3 (en) | Identifying drugs for and diagnosis of benign prostatic hyperplasia using gene expression profiles | |
| WO2001020025A3 (en) | Polymorphisms in the human cyp3a4 and cyp3a7 genes and their use in diagnostic and therapeutic applications | |
| DE19681032D2 (en) | Gene therapy nucleic acid construct, its production and use for the treatment of heart diseases | |
| WO2004050844A3 (en) | Ex vivo and in vivo expression of the thrombomodulin gene for the treatment of cardiovascular and peripheral vascular diseases | |
| WO2004050860A3 (en) | Compositions, splice variants and methods relating to colon specific genes and proteins | |
| WO2004013311A3 (en) | Compositions and methods relating to ovarian specific genes and proteins | |
| WO2001049879A3 (en) | Methods for comparing gene expression levels or patterns in normal or tumor cells | |
| WO2007038073A3 (en) | Mutations and polymorphisms of hdac11 | |
| WO2007030454A3 (en) | Mutations and polymorphisms of hdac9 | |
| WO2003066877A3 (en) | Compositions and methods relating to hepatic specific genes and proteins | |
| WO2004050858A3 (en) | Compositions, splice variants and methods relating to colon specific genes and proteins | |
| WO2003020953A3 (en) | Compositions and methods relating to colon specific genes and proteins | |
| Goyal | Development of Innovative Therapeutics and Diagnostics through Genome-Based Biomarkers: An Unexplored Potential | |
| WO2003020899A3 (en) | Compositions and methods relating to lung specific genes and proteins |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ CZ DE DE DK DK DM DZ EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ CZ DE DE DK DK DM DZ EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2388617 Country of ref document: CA |
|
| ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2001 533988 Kind code of ref document: A Format of ref document f/p: F |
|
| COP | Corrected version of pamphlet |
Free format text: PAGES 2/31-4/31, DRAWINGS, REPLACED BY NEW PAGES 2/31-4/31; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2000972316 Country of ref document: EP |
|
| WWP | Wipo information: published in national office |
Ref document number: 2000972316 Country of ref document: EP |
|
| REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |